Showing results (81-90 of 370) with videos related to

Sort By:
Pageof 37
Expert Opinion on Drug Safety|July 31, 2014
Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptomsMatthias Oelke, Adrian Gericke, Martin C Michel
Naunyn-Schmiedeberg'S Archives of Pharmacology|November 28, 2015
Longitudinal trends and subgroup analysis in publication patterns for preclinical data of newly approved drugsUrsula Köster, Ingo Nolte, Martin C Michel
Naunyn-Schmiedeberg'S Archives of Pharmacology|November 28, 2015
Preclinical research strategies for newly approved drugs as reflected in early publication patternsUrsula Köster, Ingo Nolte, Martin C Michel
British Journal of Pharmacology|March 15, 2019
β3 -Adrenoceptors in the normal and diseased urinary bladder-What are the open questions?Yasuhiko Igawa, Naoki Aizawa, Martin C Michel
Urologie (Heidelberg, Germany)|October 10, 2024
[Testosterone replacement therapy and possible side effects]Michael Zitzmann, Martin C Michel, Herbert Sperling
Naunyn-Schmiedeberg'S Archives of Pharmacology|January 28, 2009
How reliable are G-protein-coupled receptor antibodies?Martin C Michel, Thomas Wieland, Gozoh Tsujimoto
Naunyn-Schmiedeberg'S Archives of Pharmacology|June 26, 2015
A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humansMartin C Michel, Eric Mayoux, Volker Vallon
The Journal of Pharmacology and Experimental Therapeutics|October 9, 2003
Signal transduction underlying carbachol-induced contraction of rat urinary bladder. I. Phospholipases and Ca2+ sourcesTim Schneider, Peter Hein, Martin C Michel
European Journal of Pharmacology|February 15, 2011
Desirable properties of β3-adrenoceptor agonists: implications for the selection of drug development candidatesMartin C Michel, Hana Cernecka, Peter Ochodnicky
Pageof 37